79 related articles for article (PubMed ID: 25379720)
21. [Study on the relationship between polymorphisms of Cyp1A1, GSTM1, GSTT1 genes and the susceptibility to acute leukemia in the general population of Hunan province].
Liu QX; Chen HC; Liu XF; Cao YF; Zhang J; Liu J
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Dec; 26(12):975-9. PubMed ID: 16676594
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers.
Takakura S; Kohno T; Shimizu K; Ohwada S; Okamoto A; Yokota J
Oncogene; 2000 Feb; 19(6):836-40. PubMed ID: 10698503
[TBL] [Abstract][Full Text] [Related]
23. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias.
Aydin-Sayitoglu M; Hatirnaz O; Erensoy N; Ozbek U
Am J Hematol; 2006 Mar; 81(3):162-70. PubMed ID: 16493615
[TBL] [Abstract][Full Text] [Related]
24. Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response.
Kim KI; Kim TK; Kim IW; Ahn KS; Yoon SS; Shin WG; Oh JM
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):317-24. PubMed ID: 22672209
[TBL] [Abstract][Full Text] [Related]
25. Expression of the leukemia-associated gene, p18, in normal and malignant tissues; inactivation of expression in a patient with cleaved B cell lymphoma/leukemia.
Ghosh PK; Anderson J; Cohen N; Takeshita K; Atweh GF; Lebowitz P
Oncogene; 1993 Oct; 8(10):2869-72. PubMed ID: 8397372
[TBL] [Abstract][Full Text] [Related]
26. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
27. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
28. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.
You HL; Weng SW; Li SH; Wei YC; Sheu JJ; Chen CM; Huang WT
Exp Mol Pathol; 2012 Jun; 92(3):281-6. PubMed ID: 22366251
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics: technologies to detect copy number variations.
Dhawan D; Padh H
Curr Opin Mol Ther; 2009 Dec; 11(6):670-80. PubMed ID: 20072944
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis.
Hsieh YH; Chang YY; Su IJ; Yen CJ; Liu YR; Liu RJ; Hsieh WC; Tsai HW; Wang LH; Huang W
J Pathol; 2015 Jul; 236(3):337-47. PubMed ID: 25775999
[TBL] [Abstract][Full Text] [Related]
31. Regulation of Pharmacogene Expression by microRNA in The Cancer Genome Atlas (TCGA) Research Network.
Han N; Song YK; Burckart GJ; Ji E; Kim IW; Oh JM
Biomol Ther (Seoul); 2017 Sep; 25(5):482-489. PubMed ID: 28835003
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
[TBL] [Abstract][Full Text] [Related]
33. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.
Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y
Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919
[TBL] [Abstract][Full Text] [Related]
34. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma.
Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N
J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452
[TBL] [Abstract][Full Text] [Related]
35. Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population.
Nørskov MS; Frikke-Schmidt R; Bojesen SE; Nordestgaard BG; Loft S; Tybjærg-Hansen A
Pharmacogenomics J; 2011 Aug; 11(4):292-9. PubMed ID: 20514077
[TBL] [Abstract][Full Text] [Related]
36. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
Marquardt JU; Galle PR; Teufel A
Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
[TBL] [Abstract][Full Text] [Related]
37. B-cell ALL with SOX11 gene amplification associates with a worse outcome.
Angelakakis G; Varkhedi M; Dabkowski TR; Diaz MJ; Yeagley M; Blanck G
Cell Cycle; 2024 Jan; 23(1):36-42. PubMed ID: 38350028
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics in liver transplantation: testing the recipient and the ex-vivo donor liver.
Kisor DF; Bodzin AS
Pharmacogenomics; 2018 Jun; 19(9):753-756. PubMed ID: 29790414
[No Abstract] [Full Text] [Related]
39. Identification of gene-drug interactions that impact patient survival in TCGA.
Spainhour JC; Qiu P
BMC Bioinformatics; 2016 Oct; 17(1):409. PubMed ID: 27716027
[TBL] [Abstract][Full Text] [Related]
40. 6th International Symposium and expert workshops on Leukemia and Lymphoma. 17-19 March, 2005, Amsterdam, The Netherlands.
Kaspers GJ
Expert Rev Anticancer Ther; 2005 Jun; 5(3):415-7. PubMed ID: 16001949
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
